rs5029937 — TNFAIP3

TNFAIP3 Intron 2 — The Third Signal in the 6q23 Risk Cluster

The TNFAIP3 gene on chromosome 6q23 encodes A20, the primary negative regulator of NF-κB inflammatory signaling¹¹ A20, the primary negative regulator of NF-κB inflammatory signaling
A20 is a ubiquitin-editing enzyme that terminates immune activation by deubiquitinating key signaling proteins; TNFAIP3 stands for TNF Alpha Induced Protein 3. The 6q23 locus is one of the most replicated autoimmune susceptibility regions in the human genome, carrying three independently inherited risk signals that each contribute to RA and SLE susceptibility through distinct mechanisms. rs5029937 is the third and most proximally located of these signals — it sits within intron 2 of TNFAIP3 itself, in a separate linkage disequilibrium block from the intergenic variants rs6920220 and rs10499194 that lie approximately 150 kb upstream. The T allele, rare in Europeans (~3%) but substantially more common in African populations (~27%), marks a haplotype associated with elevated autoimmune disease risk, and individuals who carry it alongside the risk alleles at the upstream intergenic SNPs face the steepest combined risk at this locus.

The Mechanism

rs5029937 resides in a 71 kb LD block that is structurally distinct from the intergenic LD block containing rs6920220 and rs10499194. Its location within intron 2 of TNFAIP3 places it in a region that could influence pre-mRNA splicing, intronic regulatory elements, or enhancer activity within the gene body. The precise functional mechanism has not been resolved — like many intronic GWAS signals, rs5029937 may be a proxy for an unidentified causal variant within the same haplotype rather than directly functional itself. What is established is that it is statistically independent of the two upstream intergenic signals: conditional logistic regression²² conditional logistic regression
After conditioning on both rs6920220 and rs13207033 in multiple independent datasets, rs5029937 retained significant association with P=0.02, and combining WTCCC data showed P values reaching 4.71×10⁻¹¹ — well into genome-wide significance territory.

The downstream functional consequence is presumed to impair A20-mediated NF-κB termination, consistent with the two upstream signals that reduce A20 transcription (rs6920220) and enzymatic activity (rs2230926 F127C). Whether rs5029937 impairs A20 expression, splicing efficiency, or interacts with intronic regulatory sequences that modulate tissue-specific expression remains under investigation.

The variant shows a notable association pattern by autoantibody status³³ autoantibody status
rs5029937 was strongly associated with RF-positive and anti-CCP-positive RA cases but not with anti-CCP-negative RA in the original discovery cohort, mirroring the biology of seropositive disease where NF-κB-driven autoantibody production plays a larger role.

The Evidence

The variant was identified as one of three independent signals at 6q23 in an analysis that applied conditional logistic regression to map the locus structure. The key three-signal paper by Orozco et al. (2009) established that when rs5029937 T allele carriers also carry the rs6920220 A allele and lack the rs10499194 protective T allele, the combined odds ratio reaches 1.86⁴⁴ combined odds ratio reaches 1.86
4.4% of RA patients versus 2.3% of controls carried this highest-risk haplotype combination at 6q23. This represents one of the clearest examples of multiple independent risk signals at a single locus acting additively to substantially amplify RA susceptibility beyond any individual signal's contribution.

The RA association was originally identified in a meta-analysis and imputation study at the TNFAIP3 locus⁵⁵ meta-analysis and imputation study at the TNFAIP3 locus
Bates JS et al. 2009 — identified a 109 kb risk haplotype spanning the TNFAIP3 region, with rs5029937 among the contributing markers using European populations.

Beyond RA, rs5029937 shows broader autoimmune pleiotropism consistent with A20's role across the immune system. A meta-analysis of 18,501 SLE patients and 30,435 controls⁶⁶ meta-analysis of 18,501 SLE patients and 30,435 controls
Zhang MY et al. 2016 — pooled ORs with 95% CI across 23 studies testing TNFAIP3 polymorphisms including rs5029937, rs2230926, rs5029939, and rs3757173 found significant SLE association (P<0.001) in both European and Asian populations. A Korean case-control study⁷⁷ Korean case-control study
133 SLE patients vs 422 healthy controls; Kim SK et al. Rheumatology 2014 found rs5029937 T allele conferred OR 2.13 (95% CI 1.25–3.65, P=0.02) for SLE, while interestingly not showing significant RA association in the same cohort — echoing the population-specific and disease-specific LD patterns seen across the 6q23 locus.

A population-level RA study from Iran found the T allele associated with RA with OR 2.61 for the allele comparison (95% CI 1.38–4.92, P=0.004), and the combined TT+GT genotype versus GG showed OR 3.46 (95% CI 1.49–8.08). While this was a small cohort (50 cases/50 controls), the effect direction is consistent with European discovery data.

The T allele is very rare in Europeans (~3%) and essentially absent in some East Asian populations (dbSNP ALFA data: 0% in the small East Asian sample), while reaching ~27% frequency in African populations and ~7% in Latino populations. This population stratification has important implications: the locus likely contributes more substantially to autoimmune disease burden in African ancestry populations than European GWAS samples suggest, and population-specific LD patterns may shift the disease-relevant haplotype tagging across populations.

The VITAL randomized controlled trial⁸⁸ VITAL randomized controlled trial
25,871 participants randomized to vitamin D3 2000 IU/day, omega-3 1g/day, or placebo, followed for 5 years is the most directly actionable intervention evidence for NF-κB pathway modulation: vitamin D reduced incident autoimmune disease by 22% (HR 0.78, P=0.05) and omega-3 reduced by 15%, with benefits persisting two years after supplementation ended. These interventions act on the NF-κB pathway that TNFAIP3/A20 regulates.

Interactions

rs5029937 is the third leg of the three-signal 6q23 locus model. The complete risk hierarchy at this locus requires integrating all three signals: rs6920220 (intergenic, reduces A20 transcription), rs10499194/rs13207033 (intergenic, protective haplotype when T allele present), and rs5029937 (intronic, risk when T allele present). Carriers of both risk signals (rs6920220 A allele and rs5029937 T allele) while lacking the protective allele at rs10499194 face the maximum 6q23 combined OR of 1.86.

The TNFAIP3 missense variant rs2230926 (F127C) impairs A20 catalytic activity through a completely distinct mechanism. Carriers of rs5029937 T allele who also carry rs2230926 G allele may face compounded A20 dysfunction — the intronic variant potentially reducing expression or splicing efficiency while the missense variant reduces enzymatic function.

PTPN22 R620W (rs2476601) intersects with TNFAIP3 in seropositive autoimmune disease risk: PTPN22 lowers T-cell activation thresholds while TNFAIP3 variants prolong NF-κB inflammatory signaling. The combination of rs5029937 T allele and PTPN22 risk allele may be particularly consequential for seropositive RA risk given both variants' preferential association with RF/anti-CCP-positive disease.